Table 3.
Serum lipids and lipoproteins before and after each of the three dietary treatments
DIET TREATMENTS | |||||||
---|---|---|---|---|---|---|---|
|
Standard egg (control) |
n-3 FA enriched egg |
Walnut |
Global
P
Value
3
|
|||
Lipid variable 1 | Baseline | End 2 | Baseline | End | Baseline | End | |
Cholesterol(s) |
|
|
|
|
|||
Total (mmol/L) |
4.79 |
5.09 |
4.62 |
4.96 |
4.79 |
4.77 |
<0.0348 |
(4.67, 4.91) |
(4.92, 5.26)a |
(4.50, 4.74) |
(4.79, 5.12)ab |
(4.67, 4.92) |
(4.60, 4.94)b |
||
HDL4 (mmol/L) |
1.29 |
1.33 |
1.27 |
1.30 |
1.28 |
1.31 |
0.7736 |
(1.17, 1.41) |
(1.25, 1.41) |
(1.15, 1.40) |
(1.23, 1.38) |
(1.15, 1.40) |
(1.23, 1.39) |
||
LDL (mmol/L) |
2.75 |
3.03 |
2.63 |
2.96 |
2.81 |
2.86 |
0.2866 |
(2.63, 2.87) |
(2.87, 3.19) |
(2.50, 2.75) |
(2.80, 3.12) |
(2.69, 2.94) |
(2.70, 3.02) |
||
LDL:HDL |
2.13 |
2.31 |
2.06 |
2.32 |
2.20 |
2.19 |
0.1432 |
(2.03, 2.25) |
(2.19, 2.43) |
(1.97, 2.18) |
(2.20, 2.44) |
(2.00, 2.40) |
(2.07, 2.31) |
||
Total cholesterol:HDL |
3.71 |
3.86 |
3.63 |
3.84 |
3.76 |
3.64 |
<0.0136 |
(3.48, 4.00) |
(3.72, 4.00)a |
(3.40, 3.91) |
(3.70, 3.98)a |
(3.51, 4.05) |
(3.50, 3.79)b |
||
Triacylglycerides4 (mmol/L) |
1.15 |
1.12 |
1.13 |
0.97 |
1.13 |
0.92 |
<0.0434 |
(1.10, 1.21) |
(1.00, 1.26)a |
(1.07, 1.18) |
(0.87, 1.08)ab |
(1.07, 1.18) |
(0.83, 1.03)b |
||
Apolipoprotein A (g/L) |
1.54 |
1.62 |
1.56 |
1.59 |
1.57 |
1.59 |
0.6416 |
(1.49, 1.59) |
(1.57, 1.67) |
(1.51, 1.61) |
(1.53, 1.64) |
(1.53, 1.62) |
(1.54, 1.64) |
||
Apolipoprotein B (g/L) |
0.84 |
0.94 |
0.82 |
0.89 |
0.89 |
0.86 |
<0.0211 |
(0.77, 0.91) |
(0.90, 0.98)a |
(0.77, 0.87) |
(0.85, 0.93)ab |
(0.82, 0.96) |
(0.82, 0.90)b |
||
Triacylglycerides: Apo B4 |
1.37 |
1.10 |
1.38 |
1.02 |
1.27 |
1.01 |
0.4541 |
(1.33, 1.43) |
(0.99, 1.22) |
(1.36, 1.39) |
(0.91, 1.13) |
(1.23, 1.31) |
(0.91, 1.12) |
||
Apo B: Apo A |
0.55 |
0.59 |
0.52 |
0.56 |
0.57 |
0.54 |
0.0527 |
(0.52, 0.57) | (0.56, 0.62) | (0.51, 0.54) | (0.54, 0.59) | (0.54, 0.59) | (0.51, 0.57) |
1Values within a row with different superscript letters are significantly different, P < 0.05. All results are presented as geometric mean and 95% CI.
2End values are baseline- adjusted according to the method of Kenward and Roger.
3Mixed effects model, controlling for treatment and period effect, adjusted for multiple comparisons using Tukey-Kramer.
4Analysis performed after log-transformation. Results have been transformed back into original units and presented as geometric mean and 95% CI.